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This study examined the subsets of T lymphocytes in the
thymus, spleen and mesenteric lymph nodes as well as the
subsets of B lymphocytes in the spleen and mesenteric
lymph nodes in mice administered chitosan adipate (20
mg/kg) intraperitoneally once or four times at 24 h
intervals. The results showed that chitosan adipate
decreased the percentage of immature CD4
+CD8
+ thymic
T cells and increased the percentage of mature CD4
+ and
CD8
+ thymocytes. The most significant stimulating effect
was observed after four injections. A single exposure to
chitosan adipate increased the percentage of CD4
+
mesenteric lymph node cells, but four injections of the
drug increased the percentage of CD4
+ and CD8
+
mesenteric lymph node cells. Chitosan adipate had no
effect on the subset of splenic T cells. In contrast, chitosan
adipate administered either once or four times increased
the percentage of CD19
+ splenocytes but had no effect on
the percentage of CD19
+ mesenteric lymph node cells.
Overall, chitosan adipate induces the maturation and
differentiation of thymocytes, and regulates the number of
B splenic cells and lymph node T cells irrespective of the
number of doses.
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Introduction
A reduction in the number and function of immune cells
can lead to a secondary immunological deficency, which
manifests as recurrent infections, autoaggresion and cancer
diseases. In the last three decades, a wide variety of
substances, both natural (calf thymus extract, lysozyme
dimer) and synthetic (levamisole, isoprinosine), have been
introducted in order to modify the acquired defects of the
immune cell activity.
Recently, it was reported that chitin derivatives have
immunomodulatory action [5,13]. Chitosan (copolymer of
β-91-4)-2-amino-2-deoxy-D-glucopyranose and β-(1-4)-2-
acetamide-2-deoxy-D-glucopiranose) is an N-deacetylated
product of chitin that is produced by chemical or enzymatic
deacetylation resulting mainly in the removal of some or all
of the acetyl groups from the acetylamine groups of chitin
[1]. 
In vivo investigations have shown that chitin derivatives
are most effective as an immune adjuvant [15,18,20]. van
der Lubben et al. [18] reported that chitosan microparticles
can enhance both the systemic and local immune responses
against diphteria toxoid (DT) after being administered orally
and nasally in mice. The trials conducted on SRBC-
immunized mice confirmed the potentiating effect of a water
insoluble chitosan suspension on the humoral response in
CBA mice [8]. This suggests that chitosan injected into mice
causes an increase in the number of splenocytes producing
haemolytic anti-SRBC antibodies (PFC) and the serum
haemagglutinin titre. It was reported that chitin derivatives
such as 70% deacetylated chitin (DAC-70) could activate
peritoneal macrophages and natural killer (NK) cells,
enhance the production of antibodies and delayed-type
hypersensitivity in guinea pigs, and enhance the cell-
mediated cytotoxicity in mice [12]. However there is little
information on the influence of chitin derivatives on the T
and B lymphocyte subpopulations. Therefore this study
examined the effect of chitosan adipate on the surface
marker expression of thymus, spleen and lymph node cells
with respect to the treatment schedule.
Materials and Methods
Animals
The male and female Balb/c mice used in this study
(weighing 18-20 g, 8-10 weeks of age) were obtained from a
breeding laboratory at the Medical University, Wroc aw,
Poland.
The animals were maintained in accordance with the NIH
Guide for the Care and Use of Laboratory Animals (USA).
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Drug and treatment
Chitosan adipate at a dose of 20 mg/kg was administered
intraperitoneally either once or four times at 24 h intervals.
The process for synthesizing the chitosan adipate formed a
part of project granted by the Polish Committee for
Scientific Research (No 5PO6K04118) [1]. The volume of
each chitosan adipate dose was 0.2 ml/mouse. The control
mice received 0.2 ml of phosphate buffered saline (PBS) per
mouse instead of chitosan adipate. Each experimental group
contained eight mice.
Assay of thymocyte, splenocyte and lymphocyte of
mesenteric lymph node subpopulations
The mice were anaesthetized with halothane 24 h after the
final chitosan adipate injection. The thymus, spleen and
mesenteric lymph nodes were removed and placed in
disposable Petri dishes containing a sterile, ice-cold PBS.
The suspended cells were released from the lymphatic organs
by passing them through a nylon mesh and centrifuging
them on a layer of Ficoll 400 (Pharmacia, Sweden)/
Uropolinum 75% (diatrizoate sodium and meglumine
diatrizoate; Polpharma, Poland) at a 1 : 3 ratio and a density
of 1.071. After centrifugation at 4
oC, the cells were collected
from the interphase and washed twice with PBS supplemented
with 1% bovine serum albumin (BSA; Sigma, USA) at 4
oC.
After the second wash, the cells were suspended in PBS
with 1% BSA at 1 × 10
7 cells/ml. The viability of each cell
suspension was 90-94% according to a trypan blue dye
exclusion assay. The cells were resuspended in 100 µl PBS
solution containing 1% BSA. The thymocytes, splenocytes
and lymphocytes of the mesenteric lymph nodes were
stained with the FITC-labeled antibody to the mouse CD4
+
clone: YTS 177.9 (BioSource, Belgium) and the PE-labelled
antibody to the mouse CD8
+ clone: KT 15 (BioSource,
Belgium) at the dilution recommended by the manufacturer.
The splenocytes and lymphocytes of the mesenteric lymph
nodes were also stained with the FITC-labelled antibody to
the mouse CD3
+ clone: KT3 (BioSource, Belgium) and the
PE-labelled antibody to the mouse CD19
+ clone: 6D5
(BioSource, Belgium) at a dilution recommended by the
producer.
The cells were incubated at 4
oC for 30 min. and washed 3
times with an ice-cold PBS buffer. The fluorescence was
analysed using a flow cytometer (FACS Calibur; Becton
Dickinson, Germany). The distribution of  the thymocyte,
splenocyte and lymphocyte markers was analysed using the
Cell Quest program.
Statistical analysis
The data was analysed using a Student t-test. The differences
were considered significant at p value <0.05.
Results
The trials conducted on mice confirmed the modulating
effect of chitosan adipate on T and B-cell subpopulations
originating from the lymphatic tissue. A relationship was
observed between the stimulating effect induced by chitosan
adipate and the number of doses applied. The strongest
stimulating effect was noted after four injections of chitosan
adipate (20 mg/kg) at 24 h intervals. The changes observed
in the thymic cell subpopulations highlight the influence of
chitosan adipate on thymocyte maturation and differentiation.
The administration of chitosan adipate decreased the
percentage of immature CD4
+CD8
+ thymic cells (double-
positive cells) with corresponding increases in the percentage
of single-positive CD4
+ and CD8
+ thymocytes. The stimulating
effect depends on the number of chitosan adipate doses
applied. The strongest effect was noted after four injections
of chitosan adipate at a dose of 20 mg/kg (Table 1).
Some changes in the percentage of mesenteric lymph
node T cells were also found. The administration of chitosan
adipate once at 20 mg/kg led to an increase in the percentage
of T CD4
+ mesenteric lymph node cells but did not affect
the percentage of T CD3
+ and CD8
+ lymphocytes from the
mesenteric lymph nodes. Exposure to four chitosan adipate
doses increased the percentage of T CD4
+ and CD8
+
mesenteric lymph node cells. On the other hand, there were
no significant changes in the percentage of T splenocyte
subpopulations.
Irrespective of the number of chitosan adipate doses
applied, there was an increase in the percentage of B CD19
+
mesenteric lymph node cells but there was no effect on the
percentage of B CD19
+ splenocytes.
Discussion
It is likely that the modulating effect of chitosan adipate
on the subpopulations of T lymphocytes in the thymus and
peripheral lymphatic organs (lymph nodes) is related to
synthesis and release cytokines, particularly interleukin-1
(IL-1) and interleukin-2 (IL-2). Nishimura et al. [11] reported
that deacetylated chitin (DAC-70) induces the synthesis and
release of cytokines such as IL-1, colony-stimulating factor
(CSF) and interferons (IFN) in mice. IL-1 plays a supporting
role in the activation of T cells, partly by increasing the
expression of the IL-2 receptors on thymocytes [6,19] and
enhancing the proliferation of PHA-stimulated thymocytes
[3,9]. It is known that the maturation of T lymphocytes not
only occurs in the thymus but in other lymphatic organs as
well.
The results also show that chitosan adipate administered
to mice increases the percentage of B (CD19
+) cells in theChitosan and T and B cells in mice 159
spleen but does not alter the percentage of B lymphocytes in
the lymph nodes. It is likely that the stimulating effect of
chitosan adipate on the number of B splenocytes is due to
the activation of T lymphocytes and macrophages through
the cytokine cascade (IL-1, CSF and IFN-γ) that is enhanced
by this agent. These factors activate the functions of
polymorphonuclear cells (PMNs) and macrophages [7,10,
14,16]. IL-1 can induce the maturation of pre-B-cells [4],
This cytokine acts synergistically with various B cell growth
factors to augment proliferation, increase the level of
immunoglobulin production, and induce or augment T cells
for the production of IL-2, IL-4, IL-5 and IL-6, all of which
have immunomodulatory effects on B cells [2]. Interferons
have a significant effect in B-cell growth and differentiation.
IFN-γ acts as a regulatory agent in determining the responses
to the immunoglobulin isotype. This agent selectively enhances
the production of IgG2a while simultaneously suppressing
IgG1, IgG2b and IgG3 synthesis [17]. Iida et al. [5] reported
that the intranasal administration of chitin derivatives
(DAC-70) enhanced the production of IFN in the lung one
day after a Sendai virus infection. In addition, DAC-70
exhibited protective activity against Sendai virus and an E.
coli infection in mice. However, they reported that the
protective effect of DAC-70 depended on the treatment
schedule and the route of drug administration.
In conclusion, chitosan adipate (20 mg/kg) administered
either as a single dose or four times induces the maturation
and differentiation of thymocytes and regulates the number
of specific cluster differentiation antigens on the surface of
B splenocytes and lymph node T cells.
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